A natural protein fragment may reduce inflammation in the brain associated with Parkinson's disease.

For fifty years, the same reasoning has guided Parkinson's treatment. The medication replenishes a vital chemical that the brain loses. That strategy works—until it doesn't. Before the chemical runs out, researchers are now looking for a way to reduce inflammation in the Parkinson's disease brain.

A Brazilian team is wagering on a tiny protein fragment that the body naturally produces. Instead of repairing the damage after neurones die, it reduces inflammation in the brain.

A new target for treatment

The primary target of most Parkinson's medications is the dopamine deficiency that prevents smooth movement. In São Paulo, Brazil, a study team wondered what might happen if they instead focused on the inflammation around dead brain cells.

Cristiane Damas Gil, the head of the morphology and genetics department at the Federal University of São Paulo (UNIFESP), conducted a study motivated by this question. The trials were conducted by Luiz Philipe de Souza Ferreira, the initial author of the study.

Immune cells calm down and eliminate problems in a healthy brain. They remain activated in Parkinson's disease. Researchers have long connected the ensuing inflammation of the brain to accelerated neuronal death in animal experiments. Few had tried a direct method of calming it.

The body's own brake

The body itself served as the team's tool. A protein known as Annexin A1 is produced by both humans and mice, and it functions to stop unchecked inflammation and instruct hyperactive immune cells to stop.

The researchers employed a tiny portion of the protein, which transmits the same relaxing signal, instead of the entire protein. It is a well-known anti-inflammatory substance that has been tested for various illnesses but has never been authorised as a medication.

In this case, Annexin A1 is not a bystander. It exhibits aberrant behaviour in Parkinson's patients, according to research. sitting near the same dopamine-producing and inflammatory cells that the disease targets. Its portion was worth examining more closely because of that overlap.

Parkinson's disease in mice

The team replicated the damage because it is impossible to give a mouse Parkinson's disease in the same way that humans do. The animals' brains were directly injected with a toxin that kills nerves, destroying dopamine cells and causing the disease's stiff, stopping motions. Although it is a blunt tool, it is dependable.

They injected the fragment into the abdomen at the same time. That particular feature is important because it is considerably simpler to create a tablet or injection for a body-wide treatment that nevertheless reaches the brain than for one that is administered into the skull.

The researchers conducted the experiment twice to determine the contribution of the natural protein: once in mice that were normal and once in mice that were modified to produce no natural protein. Separating the action of the peptide from the body's own supply was the aim.

The peptide's actions

The damage to the male mice was severe, which benefited the team. Treated animals maintained many more cells alive, whereas their dopamine neurons died off in a way that made it easy to gauge how much the peptide inhibited.

Treated mice's brain tissue displayed reduced Parkinson's disease-specific cell death and calmer immunological activity. Animals administered the fragment performed better on movement tests than untreated animals.

For the first time, the study presented concrete proof that this Annexin A1 fragment can shield the neurones that Parkinson's disease kills. Following the caused injury, mice with a body-wide dosage kept more of their dopamine cells that regulate locomotion. Previous clues had suggested this, and now there was proof from a replica of a living animal.

A division between the sexes

The team's comparison of males and females produced the most bizarre findings. Female mice initially outperformed male mice in maintaining their motor skills following the Parkinson's disease-like brain lesion.

Even in females that were genetically modified to bear no Annexin A1 at all, that early advantage persisted. Early on, they appeared to be protected by something other than the protein, and this benefit gradually diminished.

Additionally, the condition disrupted the female's reproductive cycle, indicating that Parkinson's affects the hormone system in addition to the brain. Ferreira stated, "This emphasises the necessity of specific protocols for each biological sex."

Parkinson's disease disparities between the sexes are nothing new. Few have demonstrated how differentially the two sexes withstand early harm and how a body without Annexin A1 still manages in the near term. That's still a real mystery.

The gap in treatment

Levodopa, a substance that the brain transforms into the dopamine it can no longer produce, is the primary treatment for Parkinson's disease. In the early stages of the illness, it frequently has a significant impact. Later on, the problems arise. Levodopa loses its hold over time. Patients may experience

stretches and involuntary motions where the medication stops acting in between dosages. An anti-inflammatory medication would complement levodopa rather than replace it. Instead of focusing simply on the symptoms, it would target the disease's machinery. The team's damage method, which has a well-established connection to inflammation, is a typical approach to studying that machinery.

The research's next steps

There is one obvious outcome that sticks out. By reducing inflammation, a naturally occurring anti-inflammatory fragment protected dopamine neurons and enhanced mobility in a Parkinson's mouse.

There is a simple limit. The next concern is whether the peptide can undo damage that has already occurred because it acted as a guard, intervening just as the damage started. Gil stated, "Our next step is to investigate whether the peptide can reverse the damage caused by Parkinson's disease."

A medication that slows the disease itself rather than concealing its symptoms is possible if a future version is able to both prevent and reverse harm. Compared to current medications, that would be a distinct type of medication.